Submit Search
Upload
Investor Presentation
•
0 likes
•
50 views
V
vocera2016ir
Follow
Investor Presentation
Read less
Read more
Investor Relations
Report
Share
Report
Share
1 of 22
Download now
Download to read offline
Recommended
Vocera investordeck -may-15-2018web
Vocera investordeck -may-15-2018web
vocera2016ir
Vocera investordeck may 25 web 2018
Vocera investordeck may 25 web 2018
vocera2016ir
Vocera investordeck may 25 web 2018
Vocera investordeck may 25 web 2018
vocera2016ir
Vocera investordeck november 2018 web
Vocera investordeck november 2018 web
vocera2016ir
Vocera investordeck october 2018 web
Vocera investordeck october 2018 web
vocera2016ir
Vocera investordeck december 2018 web
Vocera investordeck december 2018 web
vocera2016ir
Vocera investordeck september 2018 web
Vocera investordeck september 2018 web
vocera2016ir
Vocera investordeck -june-2018-web
Vocera investordeck -june-2018-web
vocera2016ir
Recommended
Vocera investordeck -may-15-2018web
Vocera investordeck -may-15-2018web
vocera2016ir
Vocera investordeck may 25 web 2018
Vocera investordeck may 25 web 2018
vocera2016ir
Vocera investordeck may 25 web 2018
Vocera investordeck may 25 web 2018
vocera2016ir
Vocera investordeck november 2018 web
Vocera investordeck november 2018 web
vocera2016ir
Vocera investordeck october 2018 web
Vocera investordeck october 2018 web
vocera2016ir
Vocera investordeck december 2018 web
Vocera investordeck december 2018 web
vocera2016ir
Vocera investordeck september 2018 web
Vocera investordeck september 2018 web
vocera2016ir
Vocera investordeck -june-2018-web
Vocera investordeck -june-2018-web
vocera2016ir
Vocera investordeck august 2018 web version
Vocera investordeck august 2018 web version
vocera2016ir
Investor Presentation
Investor Presentation
vocera2016ir
Med releaf investor presentation aug 2017
Med releaf investor presentation aug 2017
medreleafinvestor
Med releaf investor presentation aug 23 2017 final
Med releaf investor presentation aug 23 2017 final
medreleafinvestor
Canni med investor presentation third qtr 2017
Canni med investor presentation third qtr 2017
CannimedTherapeutics
Hsah spin off merger slides final
Hsah spin off merger slides final
Vince Stanzione
1 q2018 earnings presentation 2018 apr draft v20
1 q2018 earnings presentation 2018 apr draft v20
veriskir
Med releaf investor presentation nov 2017 112817
Med releaf investor presentation nov 2017 112817
medreleafinvestor
Cats Corporate Presentation_May_2017
Cats Corporate Presentation_May_2017
RedChip Companies, Inc.
Verisk investor day 2017
Verisk investor day 2017
veriskir
Investor Presentation - April 2018
Investor Presentation - April 2018
vocera2016ir
1500090053
1500090053
veriskir
1001205097
1001205097
veriskir
Akg presentation oct-2016-final_v2-compressed
Akg presentation oct-2016-final_v2-compressed
asanko6699
Verisk investor day 2017
Verisk investor day 2017
veriskir
Dublin day deck 6.1.17 final (1)
Dublin day deck 6.1.17 final (1)
Cardinal_Health
Therapix Bioscience
Therapix Bioscience
RedChip Companies, Inc.
Vocera jp morgan_1 2 19 2pm final
Vocera jp morgan_1 2 19 2pm final
vocera2016ir
Alteryx q1'18 investor deck ir
Alteryx q1'18 investor deck ir
alteryxinvestor
Alteryx investor deck feb 2018 final
Alteryx investor deck feb 2018 final
alteryxinvestor
Vocera investordeck may 15 2018 web
Vocera investordeck may 15 2018 web
vocera2016ir
Vocera investordeck february 2018 web
Vocera investordeck february 2018 web
vocera2016ir
More Related Content
What's hot
Vocera investordeck august 2018 web version
Vocera investordeck august 2018 web version
vocera2016ir
Investor Presentation
Investor Presentation
vocera2016ir
Med releaf investor presentation aug 2017
Med releaf investor presentation aug 2017
medreleafinvestor
Med releaf investor presentation aug 23 2017 final
Med releaf investor presentation aug 23 2017 final
medreleafinvestor
Canni med investor presentation third qtr 2017
Canni med investor presentation third qtr 2017
CannimedTherapeutics
Hsah spin off merger slides final
Hsah spin off merger slides final
Vince Stanzione
1 q2018 earnings presentation 2018 apr draft v20
1 q2018 earnings presentation 2018 apr draft v20
veriskir
Med releaf investor presentation nov 2017 112817
Med releaf investor presentation nov 2017 112817
medreleafinvestor
Cats Corporate Presentation_May_2017
Cats Corporate Presentation_May_2017
RedChip Companies, Inc.
Verisk investor day 2017
Verisk investor day 2017
veriskir
Investor Presentation - April 2018
Investor Presentation - April 2018
vocera2016ir
1500090053
1500090053
veriskir
1001205097
1001205097
veriskir
Akg presentation oct-2016-final_v2-compressed
Akg presentation oct-2016-final_v2-compressed
asanko6699
Verisk investor day 2017
Verisk investor day 2017
veriskir
Dublin day deck 6.1.17 final (1)
Dublin day deck 6.1.17 final (1)
Cardinal_Health
Therapix Bioscience
Therapix Bioscience
RedChip Companies, Inc.
Vocera jp morgan_1 2 19 2pm final
Vocera jp morgan_1 2 19 2pm final
vocera2016ir
Alteryx q1'18 investor deck ir
Alteryx q1'18 investor deck ir
alteryxinvestor
Alteryx investor deck feb 2018 final
Alteryx investor deck feb 2018 final
alteryxinvestor
What's hot
(20)
Vocera investordeck august 2018 web version
Vocera investordeck august 2018 web version
Investor Presentation
Investor Presentation
Med releaf investor presentation aug 2017
Med releaf investor presentation aug 2017
Med releaf investor presentation aug 23 2017 final
Med releaf investor presentation aug 23 2017 final
Canni med investor presentation third qtr 2017
Canni med investor presentation third qtr 2017
Hsah spin off merger slides final
Hsah spin off merger slides final
1 q2018 earnings presentation 2018 apr draft v20
1 q2018 earnings presentation 2018 apr draft v20
Med releaf investor presentation nov 2017 112817
Med releaf investor presentation nov 2017 112817
Cats Corporate Presentation_May_2017
Cats Corporate Presentation_May_2017
Verisk investor day 2017
Verisk investor day 2017
Investor Presentation - April 2018
Investor Presentation - April 2018
1500090053
1500090053
1001205097
1001205097
Akg presentation oct-2016-final_v2-compressed
Akg presentation oct-2016-final_v2-compressed
Verisk investor day 2017
Verisk investor day 2017
Dublin day deck 6.1.17 final (1)
Dublin day deck 6.1.17 final (1)
Therapix Bioscience
Therapix Bioscience
Vocera jp morgan_1 2 19 2pm final
Vocera jp morgan_1 2 19 2pm final
Alteryx q1'18 investor deck ir
Alteryx q1'18 investor deck ir
Alteryx investor deck feb 2018 final
Alteryx investor deck feb 2018 final
Similar to Investor Presentation
Vocera investordeck may 15 2018 web
Vocera investordeck may 15 2018 web
vocera2016ir
Vocera investordeck february 2018 web
Vocera investordeck february 2018 web
vocera2016ir
Vocera investordeck may 2018 web
Vocera investordeck may 2018 web
vocera2016ir
Vocera investordeck august 2017 web
Vocera investordeck august 2017 web
vocera2016ir
Vocera investordeck july august 2017 web
Vocera investordeck july august 2017 web
vocera2016ir
Vocera investordeck september 2017 for web
Vocera investordeck september 2017 for web
vocera2016ir
Vocera investordeck may 12 2017 needham
Vocera investordeck may 12 2017 needham
vocera2016ir
Vocera investordeck march 2018 for web
Vocera investordeck march 2018 for web
vocera2016ir
Vocera investordeck october 2017 for web
Vocera investordeck october 2017 for web
vocera2016ir
Med releaf investor presentation july 19 2017
Med releaf investor presentation july 19 2017
medreleafinvestor
Med releaf investor presentation oct 2017 10102017
Med releaf investor presentation oct 2017 10102017
medreleafinvestor
Alteryx investor presentation 052017 final
Alteryx investor presentation 052017 final
alteryxinvestor
Vocera ir master_ february 2019 web
Vocera ir master_ february 2019 web
vocera2016ir
1001205101
1001205101
veriskir
Vocera investordeck web january 2018
Vocera investordeck web january 2018
vocera2016ir
Vocera investordeck november 2017 web (1)
Vocera investordeck november 2017 web (1)
vocera2016ir
Vocera investordeck november 2017 web
Vocera investordeck november 2017 web
vocera2016ir
Alteryx Investor Presentation 080217
Alteryx Investor Presentation 080217
alteryxinvestor
Ir q2 2017 august final 8.23
Ir q2 2017 august final 8.23
qrhc
IntelGenX Investor Presentation June 5, 2017
IntelGenX Investor Presentation June 5, 2017
ItelGenx
Similar to Investor Presentation
(20)
Vocera investordeck may 15 2018 web
Vocera investordeck may 15 2018 web
Vocera investordeck february 2018 web
Vocera investordeck february 2018 web
Vocera investordeck may 2018 web
Vocera investordeck may 2018 web
Vocera investordeck august 2017 web
Vocera investordeck august 2017 web
Vocera investordeck july august 2017 web
Vocera investordeck july august 2017 web
Vocera investordeck september 2017 for web
Vocera investordeck september 2017 for web
Vocera investordeck may 12 2017 needham
Vocera investordeck may 12 2017 needham
Vocera investordeck march 2018 for web
Vocera investordeck march 2018 for web
Vocera investordeck october 2017 for web
Vocera investordeck october 2017 for web
Med releaf investor presentation july 19 2017
Med releaf investor presentation july 19 2017
Med releaf investor presentation oct 2017 10102017
Med releaf investor presentation oct 2017 10102017
Alteryx investor presentation 052017 final
Alteryx investor presentation 052017 final
Vocera ir master_ february 2019 web
Vocera ir master_ february 2019 web
1001205101
1001205101
Vocera investordeck web january 2018
Vocera investordeck web january 2018
Vocera investordeck november 2017 web (1)
Vocera investordeck november 2017 web (1)
Vocera investordeck november 2017 web
Vocera investordeck november 2017 web
Alteryx Investor Presentation 080217
Alteryx Investor Presentation 080217
Ir q2 2017 august final 8.23
Ir q2 2017 august final 8.23
IntelGenX Investor Presentation June 5, 2017
IntelGenX Investor Presentation June 5, 2017
Recently uploaded
Osisko Gold Royalties Ltd - Q1 2024 Results
Osisko Gold Royalties Ltd - Q1 2024 Results
Osisko Gold Royalties Ltd
Western Copper and Gold - May 2024 Presentation
Western Copper and Gold - May 2024 Presentation
Paul West-Sells
AMG Quarterly Investor Presentation May 2024
AMG Quarterly Investor Presentation May 2024
gstubel
countries with the highest gold reserves in 2024
countries with the highest gold reserves in 2024
Kweku Zurek
Premium Call Girls In Kapurthala} 9332606886❤️VVIP Sonya Call Girls
Premium Call Girls In Kapurthala} 9332606886❤️VVIP Sonya Call Girls
meghakumariji156
SME IPO Opportunity and Trends of May 2024
SME IPO Opportunity and Trends of May 2024
Transique Corporate Advisors
Jual obat aborsi Tawangmangu ( 085657271886 ) Cytote pil telat bulan penggugu...
Jual obat aborsi Tawangmangu ( 085657271886 ) Cytote pil telat bulan penggugu...
Klinik kandungan
Osisko Development - Investor Presentation - May 2024
Osisko Development - Investor Presentation - May 2024
Philip Rabenok
ITAU EQUITY_STRATEGY_WARM_UP_20240505 DHG.pdf
ITAU EQUITY_STRATEGY_WARM_UP_20240505 DHG.pdf
Demetrius Brasil Faria da Silva
The Leonardo 1Q 2024 Results Presentation
The Leonardo 1Q 2024 Results Presentation
Leonardo
Teekay Corporation Q1-24 Earnings Results
Teekay Corporation Q1-24 Earnings Results
Teekay Corporation
Gorakhpur Call Girls 8250092165 Low Price Escorts Service in Your Area
Gorakhpur Call Girls 8250092165 Low Price Escorts Service in Your Area
meghakumariji156
Financial Results for the Fiscal Year Ended March 2024
Financial Results for the Fiscal Year Ended March 2024
KDDI
Osisko Gold Royalties Ltd - Corporate Presentation, May 2024
Osisko Gold Royalties Ltd - Corporate Presentation, May 2024
Osisko Gold Royalties Ltd
Terna - 1Q 2024 Consolidated Results Presentation
Terna - 1Q 2024 Consolidated Results Presentation
Terna SpA
Teekay Tankers Q1-24 Earnings Presentation
Teekay Tankers Q1-24 Earnings Presentation
Teekay Tankers Ltd
Camil Institutional Presentation_Mai24.pdf
Camil Institutional Presentation_Mai24.pdf
CAMILRI
Dubai Call Girls/// Hot Afternoon O525547819 Call Girls In Dubai
Dubai Call Girls/// Hot Afternoon O525547819 Call Girls In Dubai
kojalkojal131
Corporate Presentation Probe Canaccord Conference 2024.pdf
Corporate Presentation Probe Canaccord Conference 2024.pdf
Probe Gold
一比一原版(EUR毕业证书)鹿特丹伊拉斯姆斯大学毕业证原件一模一样
一比一原版(EUR毕业证书)鹿特丹伊拉斯姆斯大学毕业证原件一模一样
sovco
Recently uploaded
(20)
Osisko Gold Royalties Ltd - Q1 2024 Results
Osisko Gold Royalties Ltd - Q1 2024 Results
Western Copper and Gold - May 2024 Presentation
Western Copper and Gold - May 2024 Presentation
AMG Quarterly Investor Presentation May 2024
AMG Quarterly Investor Presentation May 2024
countries with the highest gold reserves in 2024
countries with the highest gold reserves in 2024
Premium Call Girls In Kapurthala} 9332606886❤️VVIP Sonya Call Girls
Premium Call Girls In Kapurthala} 9332606886❤️VVIP Sonya Call Girls
SME IPO Opportunity and Trends of May 2024
SME IPO Opportunity and Trends of May 2024
Jual obat aborsi Tawangmangu ( 085657271886 ) Cytote pil telat bulan penggugu...
Jual obat aborsi Tawangmangu ( 085657271886 ) Cytote pil telat bulan penggugu...
Osisko Development - Investor Presentation - May 2024
Osisko Development - Investor Presentation - May 2024
ITAU EQUITY_STRATEGY_WARM_UP_20240505 DHG.pdf
ITAU EQUITY_STRATEGY_WARM_UP_20240505 DHG.pdf
The Leonardo 1Q 2024 Results Presentation
The Leonardo 1Q 2024 Results Presentation
Teekay Corporation Q1-24 Earnings Results
Teekay Corporation Q1-24 Earnings Results
Gorakhpur Call Girls 8250092165 Low Price Escorts Service in Your Area
Gorakhpur Call Girls 8250092165 Low Price Escorts Service in Your Area
Financial Results for the Fiscal Year Ended March 2024
Financial Results for the Fiscal Year Ended March 2024
Osisko Gold Royalties Ltd - Corporate Presentation, May 2024
Osisko Gold Royalties Ltd - Corporate Presentation, May 2024
Terna - 1Q 2024 Consolidated Results Presentation
Terna - 1Q 2024 Consolidated Results Presentation
Teekay Tankers Q1-24 Earnings Presentation
Teekay Tankers Q1-24 Earnings Presentation
Camil Institutional Presentation_Mai24.pdf
Camil Institutional Presentation_Mai24.pdf
Dubai Call Girls/// Hot Afternoon O525547819 Call Girls In Dubai
Dubai Call Girls/// Hot Afternoon O525547819 Call Girls In Dubai
Corporate Presentation Probe Canaccord Conference 2024.pdf
Corporate Presentation Probe Canaccord Conference 2024.pdf
一比一原版(EUR毕业证书)鹿特丹伊拉斯姆斯大学毕业证原件一模一样
一比一原版(EUR毕业证书)鹿特丹伊拉斯姆斯大学毕业证原件一模一样
Investor Presentation
1.
May, 2018 Investor Presentation
2.
©2017 Vocera Communications.
All rights reserved.©2017 Vocera Communications. All rights reserved. Safe Harbor and Other Information This presentation contains “forward‐looking” statements that are based on our management’s beliefs and assumptions and on information currently available to management. We intend for such forward‐looking statements to be covered by the safe harbor provisions for forward‐looking statements contained in the U.S. Private Securities Litigation Reform Act of 1995. Forward‐looking statements include information concerning the market shifting to Vocera, the components of our mission, our accelerating operating leverage and target operating leverage model, and potential future products and services. Forward‐looking statements include all statements that are not historical facts and can be identified by terms such as “anticipates,” “believes,” “could,” “seeks,” “estimates”, “targets,” “guidance,” “expects,” “intends,” “may,” “plans,” “potential,” “predicts,” “prospects,” “projects,” “should,” “will,” “would” or similar expressions and the negatives of those terms, although not all forward‐looking statements contain these identifying words. Forward‐looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward‐looking statements. We cannot guarantee that we will achieve the plans, intentions, or expectations disclosed in our forward‐looking statements, and you should not place undue reliance on our forward‐looking statements. Forward-looking statements represent our management’s beliefs and assumptions only as of the date of this presentation. We undertake no obligation, and do not intend, to update these forward‐looking statements, to review or confirm analysts’ expectations, or to provide interim reports or updates on the progress of the current financial quarter. For a more complete discussion of factors that could materially affect our financial results and operations, please refer to our Quarterly Report on Form 10-Q for the period ended March 31, 2018 that we have filed with the SEC, including Part II, Item 1A, “Risk Factors,” and other reports that we file with the SEC. Copies of reports we file with the SEC are posted on our website and are available from us without charge. This presentation shall not constitute an offer to sell or a solicitation of an offer to purchase securities, and shall not constitute an offer, solicitation or sale in any state or jurisdiction in which or to any person to whom such an offer, solicitation or sale would be unlawful. This presentation is strictly confidential and is being made solely in reliance on applicable exemptions from the registration requirements of the Securities Act of 1933. The securities of the Company have not been registered under the Securities Act of 1933 or any state securities laws and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act of 1933 and applicable state laws. Any purchaser of such securities will be deemed to have made certain representations and acknowledgments, including, without limitation, that the purchaser is a "qualified institutional buyer" as defined in Rule 144A under the Securities Act of 1933. Statement Regarding Use of Non-GAAP Financial Measures This presentation contains certain non-GAAP financial measures. For a presentation of the most directly comparable financial measures calculated in accordance with GAAP, and a reconciliation of these non-GAAP measures to the GAAP measures, please see the appendix. The non-GAAP financial measures we present are in addition to, and not a substitute for, or superior to, financial measures calculated in accordance with GAAP. We encourage investors to carefully review our results of operations under GAAP in addition to the non-GAAP information we present to more fully understand our business. 2 Forward-Looking Statements
3.
©2017 Vocera Communications.
All rights reserved.©2017 Vocera Communications. All rights reserved. 3 • Large market shifting toward Vocera • Market leader with compelling ROI • Large wins validate sales strategy • Software acquisition extends platform • Accelerating operating leverage Our Opportunity * The Company adopted ASC 606 effective January 1, 2018. 2016 and 2017 are adjusted in accordance with the Company’s adoption of ASC 606 under the full retrospective method. Prior to the adoption of ASC 606 revenue in 2016 and 2017 was $127.7MM and $162.5MM, respectively; and A-EBITDA was 3% and 8% of revenue in 2016 and 2017, respectively. The adoption of ASC 606 did not impact 2014 or 2015. Earnings before interest, taxes, depreciation and amortization, and further excludes stock -based compensation and change in fair value of warrant and option liabilities. See Appendix for a reconciliation. Guidance was provided April 26, 2018. YoY Rev. Growth $95 $104 $132 $166 $183* -13% -3% 8% 10% 11% FY14 FY15 FY16 FY 17 FY18* Guide High-End Revenue A-EBITDA % (7%) 9% 27% 26% 10%
4.
©2017 Vocera Communications.
All rights reserved.©2017 Vocera Communications. All rights reserved. Vocera Before Vocera Now Communications Badge-Centric Point Product Department Sale Clinical Workflow Software-Centric Complete Solution Enterprise Sale Strategic Transformation 4
5.
©2017 Vocera Communications.
All rights reserved.©2017 Vocera Communications. All rights reserved. Quality ResiliencyPatient-CenteredCost Enhance how care is provided to help patients to achieve better outcomes Increase operational efficiencies Improve patient experience by allowing caregivers to be Patient Centered Improve the caregiver experience by improving workflow and empowering care teams The Quadruple Aim 5 Our Mission
6.
©2017 Vocera Communications.
All rights reserved. 6 Broadcast to OR Turnover Call on-call Orthopedic Surgeon Secure text to on-call Cardiologist Urgent call to ED Charge Nurse The Call Sheet Transformed
7.
©2017 Vocera Communications.
All rights reserved.©2017 Vocera Communications. All rights reserved. 7 Communicate, Collaborate, Make Informed Decisions Quickly PHYSICIAN ✓ Collaborate whether inside or outside the hospital NURSE ✓Reach the right person without names or numbers NURSE SUPERVISOR ✓Keep nurses and patients safer HOSPITALIST ✓Receive timely, relevant patient information HOUSEKEEPING ✓Increase bed turnover Alert & Alarm Intelligence Electronic Health Record Nurse Call Physiologic Monitor Bed Management Real-Time Location System Laboratory Info System INPUTS Dynamic Data Aggregation of Patient Events and Context OUTPUTS Context-Aware Events Response and Critical Collaboration Dynamic Master Directory
8.
©2017 Vocera Communications.
All rights reserved. 6,986 Hospitals in the U.S.(1) U.S. Hospitals 1118 (1) 8 Large Global Market Opportunity (1 ) Based on Definitive US Healthcare Database. As of December 31, 2017 International Healthcare Facilities ~250 Global Non- Healthcare Facilities ~270 ~$6 Billion Global Market Opportunity 1118 5220 Vocera Hospitals US Hospitals 18% U.S. Penetration Rate (1) (6338 Total US Hospitals) *Federal numbers are for acute care hospitals, do not include clinics or ambulatory care centers ~130 new healthcare facilities in 2017 Fed Hospitals (1) Vocera* Total (1) VA 73 164 DoD 21 46 Total 94 210 U.S. Healthcare (non hospital) 100
9.
©2017 Vocera Communications.
All rights reserved.©2017 Vocera Communications. All rights reserved. 9 Recent Platform Wins Validate Strategy MEDCOM
10.
©2017 Vocera Communications.
All rights reserved.©2017 Vocera Communications. All rights reserved. 10 The Patient Journey in a Real Time Health System Admission, discharge, transfer Test results Nurse- physician consult Obtain, clarify, change orders Update Patient status Streamline Patient flow “The RTHS uses information and communication technology to reduce the time in which patient information and medical knowledge is collected, analyzed, shared and applied.” Source: Gartner Real-Time Health System Technologies, July 2017 Requirements: • Aware • Integrated • Collaborative • Patient-Centric
11.
©2017 Vocera Communications.
All rights reserved.©2017 Vocera Communications. All rights reserved. (1) Earnings before interest, taxes, depreciation and amortization, and further excludes stock -based compensation and change in fair value of warrant and option liabilities. See appendix for a reconciliation. 2016 and 2017 are adjusted in accordance with the Company’s adoption of ASC 606 under the full retrospective method. Prior to the company’s adoption of ASC 606 revenue was $127.7 MM and $162.5MM in 2016 and 2017, respectively; and adjusted EBITDA was $4.3MM and $13.1MM in 2016 and 2017, respectively. Revenue (1) Financial Highlights Adjusted EBITDA $36.6 $40.2 $132.0 $166.0 Q117 Q118 2016 2017 ($inMillions) -$0.6 $1.8 $10.1 $16.4 Q117 Q118 2016 2017 ($inMillions) Q1 2018 Results exceeded expectations • Q1: 10% Revenue Growth, 2017: +26% • Q1: 41% Software Growth, 2017: +26% • $109.2 million Backlog + Deferred Revenue Solid Customer Base and Value Proposition • 95%+ s/w maintenance renewal rate • Strong competitive win rate Expanding Profitability and Cash Flow • A-EBITDA $16.4 million in 2017 (1) • A-EBITDA $1.8 million in Q118 • $82 million in cash on balance sheet 11 +10% +26% Financial Highlights N/MMargin (%) 4.5% 7.7% 9.9%
12.
©2017 Vocera Communications.
All rights reserved.©2017 Vocera Communications. All rights reserved. 12 % 2017 Revenue 17% Software Maintenance *All recurring 32% Professional Services *15%+ recurring 13% 38% Devices *44% recurring Diversified Revenue, High Visibility • Greater than 50% of revenues are recurring • High visibility • Low customer concentration Software *10%+ subscription *%’s are of the specific category, not company revenue.
13.
©2017 Vocera Communications.
All rights reserved.©2017 Vocera Communications. All rights reserved. Software Maintenance Professional Services Software Hardware 13 Larger Deals, Higher Software Mix $9.4M $14.9M $14.4M $3.5M $3.1M $ values are in bookings VA = New facilities added in 2017 $1.9M 31% 18% 32% 30% 13% 34% 12% 14% 13% 19% 24% 15% 39% 29% 35% 19% 56% 51% 18% 39% 20% 32% 7%
14.
©2017 Vocera Communications.
All rights reserved.©2017 Vocera Communications. All rights reserved. 14 Actual 2014 2015 2016 2017 R&D % of Revenue 17% 15% 13% 15% S&M % of Revenue 47% 41% 35% 31% G&A % of Revenue 13% 12% 11% 10% Target Model 12% 29% 8% Sales Notes • All numbers are non-GAAP, see appendix for reconciliation. • Mean peer group enterprise value comps are 3-4x Revenue and 12-15x A-EBITDA. • 2016 and 2017 reflect the company’s adoption of ASC 606. Prior to the Company’s adoption of ASC 606 the corresponding percentages would have been as follows. For 2016: 63%, 13%, 37%, 11%, 61% and 3% for Gross Margin, R&D % of Revenue, S&M % of Revenue, G&A % of Revenue, Opex % of Revenue and Adjusted EBITDA, respectively. For 2017: 64%, 16%, 32%, 10%, 58%, and 8% for Gross Margin, R&D % of Revenue, S&M % of Revenue, G&A % of Revenue, Opex % of Revenue and Adjusted EBITDA, respectively. Drivers Operating Leverage Drives Significant Value
15.
Thank you!
16.
Appendix
17.
©2017 Vocera Communications.
All rights reserved.©2017 Vocera Communications. All rights reserved. 17 GAAP to Non-GAAP Reconciliations of Net Income to Adjusted EBITDA 2014-2017 As Adjusted As Reported Change As Adjusted As Reported Change GAAP net income (loss) (10,897) (14,217) 3,320 (11,400) (17,267) 5,867 Add back: Stock compensation expense 18,196 18,196 - 12,035 12,035 - Acquisition related expenses 1,269 1,269 - 5,822 5,822 - Interest income (549) (549) - (627) (627) - Depreciation and amortization expense 7,643 7,643 - 3,770 3,770 - Provision for income taxes 759 759 - 529 529 - Non-GAAP adjusted EBITDA 16,421 13,101 3,320 10,129 4,262 5,867 As Adjusted: financials recast in accordance with the Company's adoption of ASC 606. As Reported: financials as initially reported and does not include adjustments related to the adoption of ASC 606. Year EndedDecember 31, 2017 Year EndedDecember 31, 2016 2015 2014 GAAP net loss (17,106)$ (28,297)$ Add back: Stock compensation expense 11,005 11,084 Acquisition expense - 899 Litigation expense 9 630 Restructuring expense - 654 Interest income (446) (267) Depreciation and amortization expense 3,271 3,000 Provision for income taxes 473 324 Non-GAAP adjusted EBITDA (2,794)$ (11,973)$ Twelve months endedDecember 31,
18.
©2017 Vocera Communications.
All rights reserved.©2017 Vocera Communications. All rights reserved. 18 GAAP to Non-GAAP Reconciliations of Net Income to Adjusted EBITDA Q1’18 and Q1’17
19.
©2017 Vocera Communications.
All rights reserved.©2017 Vocera Communications. All rights reserved. 19 GAAP to Non-GAAP GM & Opex Reconciliation 2017 & 2016 under ASC 606
20.
©2017 Vocera Communications.
All rights reserved.©2017 Vocera Communications. All rights reserved. 20 GAAP to Non-GAAP GM & Opex Reconciliation 2017 & 2016 under ASC 605
21.
©2017 Vocera Communications.
All rights reserved.©2017 Vocera Communications. All rights reserved. 21 GAAP to Non-GAAP Reconciliation 2015 Year ended December 31, 2015 Stock Intangible (In thousands) GAAP compensation amortization Litigation Total Non-GAAP 2015 expense (a) (b) expense (c) adjustments 2015 Reconciliation of GAAP Gross Profit to Non-GAAP Gross Profit (Unaudited) Revenue Product $ 55,716 $ — $ 55,716 Service 48,370 — 48,370 Total revenue 104,086 — — — — 104,086 Cost of revenue Product 19,666 232 323 555 19,111 Service 19,844 1,036 — 1,036 18,808 Total cost of revenue 39,510 1,268 323 — 1,591 37,919 Gross profit 64,576 (1,268) (323) — (1,591) 66,167 Reconciliation of GAAP Operating Expenses to Non-GAAP Operating Expenses (Unaudited) Research and development 16,990 1,072 — 1,072 15,918 Sales and marketing 47,647 4,486 229 4,715 42,932 General and administrative 16,734 4,179 243 9 4,431 12,303 Total operating expenses 81,371 9,737 472 9 10,218 71,153 (a) This adjustment reflects the accounting impact of non-cash stock-based compensation expense. (b) This adjustment reflects the accounting impact of acquisitions in 2010 and 2014 in non-cash expense. (c) This operating expense adjustment reflects class action litigation expenses from the August 2013 lawsuit.
22.
©2017 Vocera Communications.
All rights reserved.©2017 Vocera Communications. All rights reserved. 22 GAAP to Non-GAAP GM & Opex Reconciliation 2014 Year ended December 31, 2014 (In thousands) Reconciliation of GAAP Gross Profit to Non-GAAP Gross Profit (Unaudited) Revenue Product 51,095$ $ - 51,095$ Services 44,326 - 44,326 Total Revenue 95,421 - - - - - - 95,421 Cost of Revenue Product 18,766 254 429 72 755 18,011 Services 18,470 924 26 950 17,520 Total cost of revenue 37,236 1,178 429 - - 98 1,705 35,531 Gross profit 58,185 (1,178) (429) - - (98) (1,705) 59,890 Research and development 18,089 1,056 11 54 1,121 16,968 Sales and marketing 49,694 4,111 291 83 4,485 45,209 General and administrative 18,481 4,739 93 888 630 419 6,769 11,712 Total operating expenses 86,264 9,906 384 899 630 556 12,375 73,889 (a) This adjustment reflects the accounting impact of non-cash stock-based compensation expense. (b) This adjustment reflects the accounting impact of acquisitions in 2010 and 2014 in non-cash expense. (c) This operating expense adjustment reflects the accounting impact of acquisitions, including for Q4 2014 $800K of consideration deemed to be compensation. (d) This operating expense adjustment reflects class action litigation expenses from the August 2013 lawsuit. (e) This operating expense adjustment reflects impact of restructuring expense. Non-GAAP 2014 Reconciliation of GAAP Operating Expenses to Non-GAAP Operating Expenses (Unaudited) GAAP 2014 Stock compensation expense (a) Intangible amortization (b) Acquisiton expense (c) Litigation expense (d) Restructuring expense (e) Total Adjustments
Download now